Escolar Documentos
Profissional Documentos
Cultura Documentos
INTRODUCTION
PATHOPHYSIOLOGY
Movement of Potassium Between ICF and ECF
Normal daily potassium intake is approximately 40-100
mEq, which is absorbed from the gut, enters the ECF and
is rapidly redistributed into the intracellular compartment
due to the action of post-prandial insulin. This is essential
because an additional 100 mEq of K+ in plasma would
increase plasma K+ concentration several fold, rapidly
*Research Associate, Joshi Clinic, **Endocrinologist, Lilavati Hospital,
Bhatia Hospital and Joshi Clinic; Department of Endocrinology, Seth
GS Medical College and KEM Hospital; Mumbai. ***Associate Professor,
Mayo Clinic, Rochester, Minnesota.
www.japi.org
685
HYPOKALEMIA
Hypokalemia is defined as a plasma K+ concentration
lower than 3.5 mEq/L. 7 It occurs in about 21% of all
hospitalized patients8 and goes undertreated in nearly a
fourth of all cases.9 Clinically, diuretic use is the commonest
cause of hypokalemia.10 Manifestations of hypokalemia
are consequences of the effects on the muscle resting
membrane potential (RMP) and on the acid-base status
(described above under Pathophysiology).
In muscles, low plasma K+ leads to a hyperpolarized
myocyte that tends to be more refractory to excitation. This
causes fatigue, myalgia and weakness, most pronounced in
the large proximal skeletal muscles, like those of the hip and
thigh. Worsening hypokalemia produces respiratory muscle
weakness and, eventually, generalized muscle paralysis,
including paralytic ileus.
In cardiac myocytes, potassium ion conductance is
directly related to the plasma K+ concentration.11 Hence,
hypokalemia reduces K + conductance and leads to a
prolonged repolarization phase of the cardiac action
potential, reflected in the electrocardiogram (ECG) as a
prolonged QT (or QU) interval. Other ECG changes include
flattening or inversion of the T wave, a prominent U-wave
(Fig. 2) and ST-segment depression. Patients receiving
digitalis treatment are prone to increased toxicity in the
setting of hypokalemia because digitalis and potassium
inhibit each others binding at the Na+/K+/ATPase pump.12
Causes
There are many disease processes that lead to or include
hypokalemia (Table 1). Broadly, hypokalemia can be
caused by a shift of K+ into the intracellular compartment,
increased loss from the gut or integument, or from
www.japi.org
www.japi.org
687
www.japi.org
www.japi.org
689
HYPERKALEMIA
Hyperkalemia is defined as a plasma K+ concentration
greater than 5 mEq/L. It occurs in about 3.3% of all
hospitalized patients,41 most commonly in patients of
chronic renal insufficiency,39 and can carry a high rate
of mortality.41 As for hypokalemia, the manifestations of
hyperkalemia also relate to neuromuscular and acid-base
effects. Increased ECF K+ concentration forces K+ into the
cells through the always-open leaky potassium channels,
leading to a slight depolarization. A constant state of
depolarization affects excitability and, once again, the
effect is fatigue and weakness. If severe, respiratory muscle
weakness can be a life-threatening complication.
In cardiac myocytes, hyperkalemia causes increased
K+ conductance.11 Since the K+ current is responsible for
repolarization, the first manifestation of hyperkalemia is
a rapid repolarization, reflected on the ECG as a sharp,
peaked T wave. Increased K+ conductance also makes the
RMP more negative, to a level at which Na+ channels start
getting inactivated.42 Hyperkalemia can also induce an
atrioventricular nodal block,43 reflected as a prolonged
PR interval and a ventricular rhythm with wide QRS
complexes.42 P wave amplitude decreases, and may not
be detectable, due to an electrical paralysis of the atria.44
With increasing severity of hyperkalemia, the widened QRS
tends to merge with the peaked T wave (Fig. 4), producing
a characteristic sine wave pattern.45 Eventually, the cardiac
arrhythmia deteriorates into ventricular fibrillation or
asystole, leading to death.
Causes
The various causes of hyperkalemia fall into two main
pathophysiologic groups movement of K+ from the ICF
to the ECF and impaired renal excretion (Table 2). Factors
causing transcellular shift of K+ have already been discussed
(Fig. 1). Renal causes can, again, be either related to a
defective mineralocorticoid action or due to an intrinsic
tubular inability to secrete potassium. Oliguric renal failure
can, by virtue of reduced renal perfusion and glomerular
filtration rate (GFR), cause reduced K+ secretion. Additionally,
the initiating pathologic process may entail catabolism
and metabolic acidosis, both of which would increase
serum K+. Thus, two separate mechanisms are responsible
for hyperkalemia in oliguric renal failure. This may be
compensated by RAA axis activation, but decompensation
occurs if GFR falls below a critical value of about 10 mL/
min.
690
www.japi.org
REFERENCES
1.
2.
Jamison RL, Lacy FB, Pennell JP, Sanjana VM. Potassium secretion by
the descending limb or pars recta of the juxtamedullary nephron in
vivo. Kidney Int 1976;9:323-32.
3.
4.
5.
West ML, Marsden PA, Richardson RM, Zettle RM, Halperin ML. New
clinical approach to evaluate disorders of potassium excretion. Miner
Electrolyte Metab 1986;12:234-8.
6.
Ethier JH, Kamel KS, Magner PO, Lemann J Jr, Halperin ML. The
transtubular potassium concentration in patients with hypokalemia
and hyperkalemia. Am J Kidney Dis 1990;15:309-15.
7.
8.
www.japi.org
691
Duration
of action
Membrane effects
Calcium chloride
5-10 mL of 10% solution
Immediate
30 min.
or gluconate
IV over 2-5 min.
Intracellular shift of K+
Insulin-glucose drip
10 Units Regular insulin IV
15-30 min.
2-6 h.
with 50 mL of 50% glucose
Salbutamol
2-4 ml of 5 mg/ml salbutamol
15-30 min.
2-3 h.
by neubulizer over 15 min.
Sodium bicarbonate
50 mEq IV over 5 min.
15-30 min.
1-2 h.
Removal of excess K+
Furosemide
40-80 mg furosemide IV, with
15-60 min.
4 h.
saline if coexistent
valume depletion
Sodium polystyrene
15-30 g in 50-100 mL of 20%
1-2 h.
4-6 h.
sulfonate
sorbitol, either orally or as a
retention enema
Hemodialysis
15-30 min.
Long-term maintenance therapy
Restriction of K+ intake to < 2-3 g/day
Discontinuation of drugs interfering with K+ homeostasis
Enhanced K+ excretion: furosemide, thiazides
Fludrocortisone (in hypoaldosteronism)
Long-term sodium polystyrene sulfonate therapy
Comments
IV, Intravenously; ESRD, End-stage renal disease. Data from: Hollander-Rodriguez JC et al. (48), American Heart Association 2005 Guidelines (39) and
Gennari FJ (49).
DH. Record linkage study of hypokalaemia in hospitalized patients.
Postgrad Med J 1986;62:187-91.
21. van Uum SH, Lenders JW, Hermus AR. Cortisol, 11beta-hydroxysteroid
dehydrogenases, and hypertension. Semin Vasc Med 2004;4:12128.
9.
www.japi.org
30. Gitelman HI, Graham JB, Welt LG. A new familial disorder characterized
by hypokalemia and hypomagnesemia. Trans Assoc Am Phys
1966;79:221-23.
31. Fukuyama S, Hiramatsu M, Akagi M, Higa M, Ohta T. Novel mutations
of the chloride channel Kb gene in two Japanese patients clinically
diagnosed as Bartter syndrome with hypocalciuria. J Clin Endocrinol
Metab 2004;89:5847-50.
Physician 2006;73:283-90.
49. G e n n a r i FJ . D i s o r d e r s o f p o t a s s i u m h o m e o s t a s i s .
Hypokalemia and hyperkalemia. Crit Care Clin 2002;18:
273-88.
32. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG,
Bindels RJ. Enhanced passive Ca2+ reabsorption and reduced Mg2+
channel abundance explains thiazide-induced hypocalciuria and
hypomagnesemia. J Clin Invest 2005;115:1651-58.
33. Halperin ML, Richarson RMA, Bear RA, Magner PO, Kamel K, Ethier
J. Urine ammonium: the key to the diagnosis of distal renal tubular
acidosis. Nephron 1988;50:1-4.
34. Buckalew VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol
1989;141(3 Pt 2):731-37.
35. Ring T, Frische S, Nielsen S. Clinical review: Renal tubular
acidosisa physicochemical approach. Crit Care 2005;9:
573-80.
36. Shah GN, Bonapace G, Hu PY, Strisciuglio P, Sly WS. Carbonic
anhydrase II deficiency syndrome (osteopetrosis with renal tubular
acidosis and brain calcification): novel mutations in CA2 identified by
direct sequencing expand the opportunity for genotype-phenotype
correlation. Hum Mutat 2004;24:272.
37. Kim HJ, Han SW. Therapeutic approach to hyperkalemia. Nephron
2002;92(suppl 1):33-40.
38. Glover P. Hypokalaemia. Crit Care Resusc 1999;1:239-51.
39. 2005 American Heart Association Guidelines for Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care. Part 10.1: LifeThreatening Electrolyte Abnormalities. Circulation 2005;112:IV-121IV-125.
40. Mount DB, Zandi-Nejad K. Disorders of Potassium Balance. In: Brenner
BM, Rector FC, Livine SA, editors: The Kidney. 7th ed. Philadelphia: WB
Saunders; 2002. p. 1015.
41. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int
Urol Nephrol 2000;32:177-80.
42. Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald E,
Zipes DP, Libby P, editors: Heart Disease: A Textbook of Cardiovascular
Medicine. 6th ed. Philadelphia: WB Saunders; 2001.
43. Ohmae M, Rabkin SW. Hyperkalemia-induced bundle branch block
and complete heart block. Clin Cardiol 1981;4:43-6.
44. Spodick DH. Effects of severe hyperkalemia. Am Heart Hosp
2008;6:68.
45. M a t t u A , B r a d y WJ, Pe r ro n A D. E l e c t ro c a rd i o g r a p h i c
manifestations of hypothermia. Am J Emerg Med 2000;18:
721-29.
46. Oh MS, Carroll HJ, Clemmons JE, Vagnucci AH, Levison SP, Whang ES.
A mechanism for hyporeninemic hypoaldosteronism in chronic renal
disease. Metabolism 1974;23:1157-66.
47. Chang SS, Grunder S, Hanukoglu A, Rsler A, Mathew PM, Hanukoglu
I, et al. Mutations in subunits of the epithelial sodium channel cause
salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism
type 1. Nat Genet 1996;12:248-53.
48. Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam
www.japi.org
693